Therapure has signed a variety of fill/finish contracts recently, demonstrating the flexibility of our Health Canada licensed facility
Toronto, ON (Vocus) March 29, 2010
Therapure Biopharma Inc. today announced a fill/finish contract with Kane Biotech Inc. (V.KNE), a Canadian biotechnology company based in Winnipeg, Manitoba. Under the terms of the agreement, Therapure will provide custom fill/finish services for a key development-stage product for Kane Biotech. Financial terms were not disclosed.
Kane Biotech is a biotechnology company engaged in the development of products to prevent and disperse biofilms. Biofilms are a major cause of a number of serious medical problems including chronic infections and medical device related infections. Biofilms develop on surfaces such as catheters, prosthetic implants, teeth, lungs and the urogenital tract. Biofilms are pervasive, costly to deal with and approximately 80% of all human bacterial infections involve biofilms. The healing of chronic wounds alone costs the US health care system $20 billion per year.
“Therapure has signed a variety of fill/finish contracts recently, demonstrating the flexibility of our Health Canada licensed facility” said Thomas Wellner, President and CEO of Therapure. "Our agreement with Kane Biotech includes hand-fill services conducted under Good Manufacturing Practices standards," continued Mr. Wellner.
"Therapure was quick to provide a detailed service proposal that clearly indicated they understood our requirements," said Gord Froehlich, President and CEO of Kane. "We look forward to working closely with Therapure as we advance out products through the approval process," Mr. Froehlich concluded.
About Therapure Biopharma Inc.:
Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies and packages therapeutic proteins. As a contract development and manufacturing organization (CDMO) Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an intimate understanding of advanced biology, complex proteins, and regulatory processes to develop effective and innovative solutions to advance products from discovery to market for its clients. Therapure’s Health Canada licensed 130,000 sq. ft. facility, includes manufacturing, research and quality control laboratories and a cGMP warehouse, and is built to U.S. FDA, EMEA, MHRA and Health Canada standards for the aseptic handling and purification of proteins.
For more information, please visit: http://www.therapurebio.com
Thomas Wellner, President and CEO
Therapure Biopharma Inc.
+1 905 286-6204
ceo (at) therapurebio (dot) com